| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash (used in) provided by financing activities | -25,745 | -14,440 |
| Net increase in cash and cash equivalents | 12,648 | 23,025 |
| Cash and cash equivalents at beginning of period | 64,696 | - |
| Cash and cash equivalents at end of period | 77,344 | - |
Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. (AVIR)